CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands |
Preferred Stock
Series A
|
Preferred Stock
Series B
|
Preferred Stock
Convertible preferred stock
|
Common Stock |
Additional Paid-In Capital |
Accumulated Other Comprehensive Income |
Accumulated Deficit |
Total |
Balance at beginning of period at Dec. 31, 2022 |
$ 49
|
|
|
$ 86
|
$ 1,306,271
|
|
$ (1,182,392)
|
$ 124,014
|
Balance at beginning of period (in shares) at Dec. 31, 2022 |
984,000
|
2,000
|
5,000
|
11,454,000
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
|
Issuance of common stock related to 401(k) contribution |
|
|
|
|
123
|
|
|
123
|
Issuance of common stock related to 401(k) contribution (in shares) |
|
|
|
7,000
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
1,570
|
|
|
1,570
|
Preferred stock dividends |
|
|
|
|
(1,368)
|
|
|
(1,368)
|
Net income (loss) |
|
|
|
|
|
|
(9,813)
|
(9,813)
|
Balance at end of period at Mar. 31, 2023 |
$ 49
|
|
|
$ 86
|
1,306,596
|
|
(1,192,205)
|
114,526
|
Balance at end of period (in shares) at Mar. 31, 2023 |
984,000
|
2,000
|
5,000
|
11,461,000
|
|
|
|
|
Balance at beginning of period at Dec. 31, 2022 |
$ 49
|
|
|
$ 86
|
1,306,271
|
|
(1,182,392)
|
124,014
|
Balance at beginning of period (in shares) at Dec. 31, 2022 |
984,000
|
2,000
|
5,000
|
11,454,000
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
|
|
(20,722)
|
Balance at end of period at Sep. 30, 2023 |
$ 49
|
|
|
$ 86
|
1,308,943
|
|
(1,203,114)
|
105,964
|
Balance at end of period (in shares) at Sep. 30, 2023 |
984,000
|
2,000
|
5,000
|
11,472,000
|
|
|
|
|
Balance at beginning of period at Dec. 31, 2022 |
$ 49
|
|
|
$ 86
|
1,306,271
|
|
(1,182,392)
|
124,014
|
Balance at beginning of period (in shares) at Dec. 31, 2022 |
984,000
|
2,000
|
5,000
|
11,454,000
|
|
|
|
|
Balance at end of period at Dec. 31, 2023 |
$ 49
|
|
|
$ 86
|
1,311,809
|
|
(1,223,223)
|
88,721
|
Balance at end of period (in shares) at Dec. 31, 2023 |
984,000
|
2,000
|
5,000
|
11,495,000
|
|
|
|
|
Balance at beginning of period at Mar. 31, 2023 |
$ 49
|
|
|
$ 86
|
1,306,596
|
|
(1,192,205)
|
114,526
|
Balance at beginning of period (in shares) at Mar. 31, 2023 |
984,000
|
2,000
|
5,000
|
11,461,000
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
|
Exercise of stock options |
|
|
|
|
153
|
|
|
153
|
Exercise of stock options (in shares) |
|
|
|
8,000
|
|
|
|
|
Issuance of common stock related to ESPP |
|
|
|
|
50
|
|
|
50
|
Issuance of common stock related to ESPP (in shares) |
|
|
|
3,000
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
2,163
|
|
|
2,163
|
Preferred stock dividends |
|
|
|
|
(1,368)
|
|
|
(1,368)
|
Net income (loss) |
|
|
|
|
|
|
(5,400)
|
(5,400)
|
Balance at end of period at Jun. 30, 2023 |
$ 49
|
|
|
$ 86
|
1,307,594
|
|
(1,197,605)
|
110,124
|
Balance at end of period (in shares) at Jun. 30, 2023 |
984,000
|
2,000
|
5,000
|
11,472,000
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
2,717
|
|
|
2,717
|
Preferred stock dividends |
|
|
|
|
(1,368)
|
|
|
(1,368)
|
Net income (loss) |
|
|
|
|
|
|
(5,509)
|
(5,509)
|
Balance at end of period at Sep. 30, 2023 |
$ 49
|
|
|
$ 86
|
1,308,943
|
|
(1,203,114)
|
105,964
|
Balance at end of period (in shares) at Sep. 30, 2023 |
984,000
|
2,000
|
5,000
|
11,472,000
|
|
|
|
|
Balance at beginning of period at Dec. 31, 2023 |
$ 49
|
|
|
$ 86
|
1,311,809
|
|
(1,223,223)
|
88,721
|
Balance at beginning of period (in shares) at Dec. 31, 2023 |
984,000
|
2,000
|
5,000
|
11,495,000
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
|
Exercise of stock options |
|
|
|
$ 1
|
621
|
|
|
622
|
Exercise of stock options (in shares) |
|
|
|
135,000
|
|
|
|
|
Issuance of common stock related to 401(k) contribution |
|
|
|
|
118
|
|
|
118
|
Issuance of common stock related to 401(k) contribution (in shares) |
|
|
|
7,000
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
2,856
|
|
|
2,856
|
Preferred stock dividends |
|
|
|
|
(1,368)
|
|
|
(1,368)
|
Repurchase of common stock |
|
|
|
|
|
|
(13)
|
(13)
|
Repurchase of common stock (in shares) |
|
|
|
(1,000)
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
|
(8,595)
|
(8,595)
|
Balance at end of period at Mar. 31, 2024 |
$ 49
|
|
|
$ 87
|
1,314,036
|
|
(1,231,831)
|
82,341
|
Balance at end of period (in shares) at Mar. 31, 2024 |
984,000
|
2,000
|
5,000
|
11,636,000
|
|
|
|
|
Balance at beginning of period at Dec. 31, 2023 |
$ 49
|
|
|
$ 86
|
1,311,809
|
|
(1,223,223)
|
$ 88,721
|
Balance at beginning of period (in shares) at Dec. 31, 2023 |
984,000
|
2,000
|
5,000
|
11,495,000
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
|
Exercise of stock options (in shares) |
|
|
|
|
|
|
|
246,599
|
Repurchase of common stock |
|
|
|
|
|
|
|
$ (13)
|
Repurchase of common stock (in shares) |
|
|
|
|
|
|
|
(660)
|
Net unrealized gain on available-for-sale debt securities |
|
|
|
|
|
|
|
$ 104
|
Net income (loss) |
|
|
|
|
|
|
|
(9,853)
|
Balance at end of period at Sep. 30, 2024 |
$ 49
|
|
|
$ 88
|
1,317,657
|
$ 104
|
(1,233,089)
|
84,809
|
Balance at end of period (in shares) at Sep. 30, 2024 |
984,000
|
2,000
|
5,000
|
11,755,000
|
|
|
|
|
Balance at beginning of period at Mar. 31, 2024 |
$ 49
|
|
|
$ 87
|
1,314,036
|
|
(1,231,831)
|
82,341
|
Balance at beginning of period (in shares) at Mar. 31, 2024 |
984,000
|
2,000
|
5,000
|
11,636,000
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
|
Exercise of stock options |
|
|
|
|
250
|
|
|
250
|
Exercise of stock options (in shares) |
|
|
|
15,000
|
|
|
|
|
Issuance of common stock related to ESPP |
|
|
|
|
95
|
|
|
95
|
Issuance of common stock related to ESPP (in shares) |
|
|
|
7,000
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
2,690
|
|
|
2,690
|
Preferred stock dividends |
|
|
|
|
(1,368)
|
|
|
(1,368)
|
Net income (loss) |
|
|
|
|
|
|
15,985
|
15,985
|
Balance at end of period at Jun. 30, 2024 |
$ 49
|
|
|
$ 87
|
1,315,703
|
|
(1,215,846)
|
99,993
|
Balance at end of period (in shares) at Jun. 30, 2024 |
984,000
|
2,000
|
5,000
|
11,658,000
|
|
|
|
|
Increase (Decrease) in Stockholders' Equity |
|
|
|
|
|
|
|
|
Exercise of stock options |
|
|
|
$ 1
|
732
|
|
|
733
|
Exercise of stock options (in shares) |
|
|
|
97,000
|
|
|
|
|
Stock-based compensation expense |
|
|
|
|
2,590
|
|
|
2,590
|
Preferred stock dividends |
|
|
|
|
(1,368)
|
|
|
$ (1,368)
|
Repurchase of common stock (in shares) |
|
|
|
|
|
|
|
0
|
Net unrealized gain on available-for-sale debt securities |
|
|
|
|
|
104
|
|
$ 104
|
Net income (loss) |
|
|
|
|
|
|
(17,243)
|
(17,243)
|
Balance at end of period at Sep. 30, 2024 |
$ 49
|
|
|
$ 88
|
$ 1,317,657
|
$ 104
|
$ (1,233,089)
|
$ 84,809
|
Balance at end of period (in shares) at Sep. 30, 2024 |
984,000
|
2,000
|
5,000
|
11,755,000
|
|
|
|
|